Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure

Description

Right ventricular (RV) failure is recognized to worsen patient outcomes in the setting of heart failure with reduced ejection fraction (HFrEF)-related pulmonary hypertension (PH), yet the investigators fall short in trying to identify and treat it. The current proposal will (1) determine the best clinical indicators of intrinsic RV myocyte contractile failure in humans with HFrEF-PH, (2) clarify underlying mechanisms, and (3) test novel treatments on RV myocytes. The long-term goal of this proposal will be to better identify and treat RV failure in humans suffering from HFrEF-PH.

Conditions

Heart Failure With Reduced Ejection Fraction, Pulmonary Hypertension, Right Heart Failure Due to Left Heart Failure

Study Overview

Study Details

Study overview

Right ventricular (RV) failure is recognized to worsen patient outcomes in the setting of heart failure with reduced ejection fraction (HFrEF)-related pulmonary hypertension (PH), yet the investigators fall short in trying to identify and treat it. The current proposal will (1) determine the best clinical indicators of intrinsic RV myocyte contractile failure in humans with HFrEF-PH, (2) clarify underlying mechanisms, and (3) test novel treatments on RV myocytes. The long-term goal of this proposal will be to better identify and treat RV failure in humans suffering from HFrEF-PH.

Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure

Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure

Condition
Heart Failure With Reduced Ejection Fraction
Intervention / Treatment

-

Contacts and Locations

Baltimore

Johns Hopkins Hospital, Baltimore, Maryland, United States, 21287

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adult patients aged between 18 and 90 years of age
  • * Diagnosed with heart failure with reduced ejection fraction (LV ejection fraction ≤ 40%)
  • * Can safely hold direct oral anticoagulant (DOAC) vitamin K antagonist (VKA) for 48 hours prior to the procedure
  • * Unable to interrupt VKA anticoagulation
  • * Point of care International Normalized Ratio (INR) \> 1.5
  • * Pregnant patients
  • * Acute hospitalization or decompensation within 2 weeks prior to study date
  • * Participation in a study involving an investigational drug within 4 weeks prior to study date
  • * Inability to lie flat in the supine position
  • * Symptomatic hemodynamic instability at rest or during the procedure

Ages Eligible for Study

18 Years to 90 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Johns Hopkins University,

Steven Hsu, MD, PRINCIPAL_INVESTIGATOR, Johns Hopkins School of Medicine

Study Record Dates

2029-03-31